INTRODUCTION
The increasing use of immunosuppressive agents after transplantations has made more complications. Among these, neurological side effects of carcineurin inhibitor are becoming controversial recently. The neurological change related to tacrolimus was first presented as posterior reversible leukoencephalopathy in 1996 [1] . Until now, there have been many clinical symptoms reported and they are referred to various names including posterior reversible encephalopathy syndrome. We report an 11-year-old girlʹs reversible cerebral infarction and cerebral vascular stenosis after using tacrolimus for her kidney transplantation.
CASE REPORT
An 11-year-old girl with end-stage renal disease had underwent a transplantation of kidney from her mother. Pretransplant donor-specific T-and B-cell cross-matches were negative. Initial immunosuppressive treatment consisted of tacrolimus (0.2 ng/kg/day orally, target level 15 to 20 ng/mL), mycophenolate mofetil (1,000 mg twice a day orally), and methylprednisolone (25 mg twice a day orally).
Tacrolimus levels remained within the target range during the first ten days. Renal function was quite good after kidney transplantation. On post-operative day 12, hypertension (160/100), headache, and left motor weakness (Fig. 2) . This neurological change seems to be acute cerebral infarction due to cerebral vascular stenosis caused by either vasculitis or vascular spasm, which is highly suspected to be the consequence of tacrolimus. We decided to change from tacrolimus to cyclosporine. Two days after the change, the cyclosporine level was 232.64 ng/mL. Afterwards, neurologic symptoms improved and follow-up (post-operative day # 29) brain MRI and MRA findings showed an improving status of multifocal acute infarction and no stenosis of either ACA or MCA (Fig. 3) . At the 40th postoperative day, left motor weakness improved to grade IV, and rehabilitation treatment was ongoing.
DISCUSSION
In 1996, Hinchey et al. [1] 
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There have been many reports of this syndrome in the literature since its initial definition.
As PRES has become better recognized, many contributing factors have been identified. For example, reports have linked PRES to hypertension, immunosuppressive/chemotherapeutic agents, eclampsia, porphyria, and renaldysfunction [3, 4] . The incidence of neurotoxicity, which is one of the major adverse events of calcineurin inhibitors, was higher in patients receiving tacrolimus rather than cyclosporine. As both sensory and motor functions may be adversely affected, patients thus present with a wide range of neurological and psychiatric disorders. ing the drug for a few days [7] . Failure to recognize its heralding symptoms may potentially increase morbidity in organ transplantation. Therefore, careful examination of patients receiving immunosuppressive agents was needed to discover this uncommon but good prognostic complication.
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